Berotralstat for long-term prophylaxis of hereditary angioedema in Japan: Parts 2 and 3 of the randomized APeX-J Phase III trial

Berotralstat for long-term prophylaxis of hereditary angioedema in Japan: Parts 2 and 3 of the randomized APeX-J Phase III trial

Background: Berotralstat is a once-daily oral inhibitor of plasma kallikrein for the prophylaxis of hereditary angioedema (HAE) in patients ≥12 years. APeX-J aimed to evaluate the efficacy and safety of berotralstat in Japan. Methods: APeX-J was a Phase III trial comprising 3 parts (NCT03873116). Pa...

Full description

Bibliographic Details
Main Authors: Daisuke Honda, MD, PhD, Michihiro Hide, MD, PhD, Tomoo Fukuda, MD, PhD, Keisuke Koga, MD, PhD, Eishin Morita, MD, PhD, Shinichi Moriwaki, MD, Yoshihiro Sasaki, MD, PhD, Yusuke Suzuki, MD, PhD, Phil Collis, PhD, Douglas T. Johnston, DO, Dianne Tomita, MPH, Bhavisha Desai, PharmD, Isao Ohsawa, MD, PhD
Format: Article
Language:English
Published: Elsevier 2024-03-01
Series:World Allergy Organization Journal
Subjects:
Angioedemas
Hereditary
Berotralstat
Japan
Plasma kallikrein
Quality of life
Online Access:http://www.sciencedirect.com/science/article/pii/S1939455124000139

Internet

http://www.sciencedirect.com/science/article/pii/S1939455124000139

Similar Items